The rounds this investor is named on, who it invests beside, and where it shows up.
Named on 10 rounds in the feed, most often at Series A and in Biotech.
Venture capitalthirdrockventures.comRounds from 2021-05-13 to 2026-06-30
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Flare Therapeutics A biotech startup targeting transcription factors | Series C Verified against 5 sources[ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $85M | 2026-06-30 | [ LEAD ] |
Terremoto Cutting-edge small-molecule therapies for cancer and other diseases targeted primarily at healthcare providers and researchers. |
Series C Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. |
| $108M |
| 2026-04-15 |
| [ PART ] |
Syremis Therapeutics Syremis Therapeutics is a clinical-stage biopharmaceutical company developing novel medicines to make a profound impact on the treatment of mental health. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $165M | 2025-12-18 | [ LEAD ] |
ArtBio ARTBIO develops alpha radioligand therapies focused on cancer treatment aimed at healthcare providers and patients. | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $132M | 2025-07-29 | [ PART ] |
Merida Biosciences Merida Biosciences develops precision therapies for autoimmune-driven diseases targeting pathogenic drivers of antibody-driven diseases. | Series A Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $121M | 2025-04-08 | [ LEAD ] |
ArtBio ARTBIO develops alpha radioligand therapies focused on cancer treatment aimed at healthcare providers and patients. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $90M | 2023-12-07 | [ LEAD ] |
Terremoto Cutting-edge small-molecule therapies for cancer and other diseases targeted primarily at healthcare providers and researchers. | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $175M | 2023-11-02 | [ PART ] |
Flare Therapeutics A biotech startup targeting transcription factors | Series B Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $123M | 2023-03-22 | [ PART ] |
Terremoto Cutting-edge small-molecule therapies for cancer and other diseases targeted primarily at healthcare providers and researchers. | Series A Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $75M | 2022-05-25 | [ LEAD ] |
Flare Therapeutics A biotech startup targeting transcription factors | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $82M | 2021-05-13 | [ LEAD ] |